HomeProductsBuilding BlocksHeterocyclic ScaffoldsBenzoxazolesBrensocatib
Chemical structure of CAS 1802148-05-5

Brensocatib

CAS No.1802148-05-5
MDL No.N/A
MFC23H24N4O4
MW420.50
InChI KeyAEXFXNFMSAAELR-RXVVDRJESA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1802148-05-5
Product NameBrensocatib

Biological Targets

CTSC

Associated Conditions

cystic fibrosis·kidney disease·Bronchiectasis·COVID-19·liver disease
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial.

The Lancet. Respiratory medicine • Vol. 10, Issue 12 • 2022
PMID: 36075243PMC: PMC9442496DOI: 10.1016/S2213-2600(22)00261-2

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020
PMID: 32020584PMC: PMC7160657DOI: 10.1111/imm.13175

Dipeptidyl Peptidase 1 Inhibitor AZD7986 Induces a Sustained, Exposure-Dependent Reduction in Neutrophil Elastase Activity in Healthy Subjects.

Clinical pharmacology and therapeutics • Vol. 104, Issue 6 • 2018
PMID: 29484635PMC: PMC6282495DOI: 10.1002/cpt.1053

Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986).

Journal of medicinal chemistry • Vol. 59, Issue 20 • 2016
PMID: 27690432DOI: 10.1021/acs.jmedchem.6b01127

Documentation

Similar Products